Shanghai No.1 Pharmacy Co.,Ltd. (SHA:600833)
China · Delayed Price · Currency is CNY 10.72
+0.05 (0.47%)
Sep 8, 2026, 11:29 AM CST
Shanghai No.1 Pharmacy Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,055 | 2,070 | 1,864 | 1,767 | 2,617 | 1,342 |
Other Revenue | 59.74 | 59.74 | 51.35 | 52.23 | 38.5 | 56.25 |
| 2,115 | 2,130 | 1,915 | 1,820 | 2,656 | 1,398 | |
Revenue Growth | 4.79% | 11.23% | 5.26% | -31.49% | 89.94% | -11.89% |
Cost of Revenue | 1,790 | 1,790 | 1,598 | 1,474 | 2,116 | 1,153 |
Gross Profit | 325.19 | 340.08 | 317.2 | 345.21 | 540.36 | 244.86 |
Selling, General & Admin | 329.74 | 339.61 | 318.56 | 315.85 | 307.58 | 230.69 |
Other Operating Expenses | 5.64 | 5.96 | 5.88 | 8.36 | 9.53 | 4.71 |
Operating Expenses | 337.87 | 346.04 | 305.27 | 333.8 | 333.73 | 235.93 |
Operating Income | -12.68 | -5.97 | 11.93 | 11.41 | 206.63 | 8.94 |
Interest Expense | -3.61 | -4.51 | -6.05 | -7.59 | -14.12 | -3.15 |
Interest & Investment Income | 21.05 | 25.09 | 33.86 | 25.31 | 17.89 | 24.23 |
Currency Exchange Gain (Loss) | -1.59 | -1.59 | -0.18 | 0.19 | 0.05 | - |
Other Non Operating Income (Expenses) | -5.25 | -0.8 | 3.42 | -3.4 | -3.94 | 0.26 |
EBT Excluding Unusual Items | -2.09 | 12.22 | 42.98 | 25.92 | 206.51 | 30.27 |
Gain (Loss) on Sale of Investments | 0.24 | -0.01 | 0.38 | 12.14 | 0.29 | - |
Gain (Loss) on Sale of Assets | 80.16 | 49.84 | 168.89 | 64.73 | -0.07 | 1.23 |
Asset Writedown | -1.3 | -1.3 | -4.99 | -4.69 | -19.99 | - |
Other Unusual Items | 15.3 | 15.3 | 9.02 | 19.41 | 3.79 | 33.75 |
Pretax Income | 92.31 | 76.05 | 216.27 | 117.51 | 190.52 | 65.24 |
Income Tax Expense | 21.6 | 17.51 | 52.66 | 28.24 | 46.96 | 15.82 |
Earnings From Continuing Operations | 70.71 | 58.54 | 163.62 | 89.28 | 143.56 | 49.42 |
Minority Interest in Earnings | -0.81 | -0.79 | -0.55 | - | - | - |
Net Income | 69.89 | 57.75 | 163.06 | 89.28 | 143.56 | 49.42 |
Net Income to Common | 69.89 | 57.75 | 163.06 | 89.28 | 143.56 | 49.42 |
Net Income Growth | 47.78% | -64.59% | 82.65% | -37.81% | 190.49% | -27.90% |
Shares Outstanding (Basic) | 222 | 222 | 223 | 223 | 224 | 225 |
Shares Outstanding (Diluted) | 222 | 222 | 223 | 223 | 224 | 225 |
Shares Change | -0.51% | -0.57% | 0.08% | -0.50% | -0.14% | 1.60% |
EPS (Basic) | 0.31 | 0.26 | 0.73 | 0.40 | 0.64 | 0.22 |
EPS (Diluted) | 0.31 | 0.26 | 0.73 | 0.40 | 0.64 | 0.22 |
EPS Growth | 48.53% | -64.38% | 82.50% | -37.50% | 190.91% | -29.03% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 41.2 | 72.95 | -2.91 | 44.61 | 120.94 | 23.92 |
Free Cash Flow Per Share | 0.18 | 0.33 | -0.01 | 0.20 | 0.54 | 0.11 |
Dividend Per Share | 0.078 | 0.078 | 0.220 | 0.125 | 0.195 | 0.070 |
Dividend Growth | -64.55% | -64.55% | 76.00% | -35.90% | 178.57% | -26.32% |
Gross Margin | 15.37% | 15.96% | 16.56% | 18.97% | 20.34% | 17.51% |
Operating Margin | -0.60% | -0.28% | 0.62% | 0.63% | 7.78% | 0.64% |
Profit Margin | 3.30% | 2.71% | 8.51% | 4.91% | 5.41% | 3.53% |
Free Cash Flow Margin | 1.95% | 3.43% | -0.15% | 2.45% | 4.55% | 1.71% |
EBITDA | -5.38 | 1.3 | 19.43 | 18.79 | 214.25 | 16.71 |
EBITDA Margin | -0.25% | 0.06% | 1.01% | 1.03% | 8.07% | 1.20% |
D&A For EBITDA | 7.3 | 7.26 | 7.51 | 7.38 | 7.62 | 7.77 |
EBIT | -12.68 | -5.97 | 11.93 | 11.41 | 206.63 | 8.94 |
EBIT Margin | -0.60% | -0.28% | 0.62% | 0.63% | 7.78% | 0.64% |
Effective Tax Rate | 23.40% | 23.03% | 24.35% | 24.03% | 24.65% | 24.25% |
Revenue as Reported | 2,115 | 2,130 | 1,915 | 1,820 | 2,656 | 1,398 |
Advertising Expenses | - | 5.08 | 6.11 | 6.6 | 4.75 | 2.99 |